611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Only Select Incidental Thyroid Nodules Need Further EvaluationTravelers Bring Malaria Back to U.S., With High CostsThe Top 5 Conditions That Shorten Americans' Lives -- And Are PreventableHealth Tip: Dealing With Foot ArthritisCDC: Salmonella Infection Prevalence Down in 2016Do Diet Sodas Pose Health Risks?Hantavirus Pulmonary Syndrome Risk Up for Some PopulationsHealth Tip: When Asthma Doesn't ImproveHealth Tip: Help Manage ConstipationChagas Disease Presents Public Health Challenge in the U.S.FDA Approves Device to Help Curb Cluster HeadachesReview: Interventions Don't Promote Exercise in Rural AdultsDiffering Statin Guidelines Leave Many Clinicians UncertainIllness From 'Kissing Bug' Now Widespread in U.S.Conflicting Statin Guidelines Leave Millions in 'Gray Zone'No Link Between Common Antibiotic, Irregular HeartbeatEpilepsy: Another Potential Zika Threat to BabiesUveitis Risk Higher Among Individuals With PsoriasisOne in Five Post-Op Patients Need Unscheduled HelpNew Bowel Disorder Treatments Needed, FDA SaysWhat's the Best Seasonal Allergy Med for Your Kid?Another Type of Mosquito May Carry ZikaCould a Daily Vitamin Curb Smog's Effect on the Heart?Accurate Diagnosis of Endocrine Hypertension ImportantKidney Disease a Big Contributor to Heart-Related Deaths: StudyOverweight, Underweight Both Tied to MigrainesDon't Let Ticks Get Under Your SkinSpecific Factors Influence First-Line Biologic Rx for PsoriasisA Healthier Weight May Mean Fewer MigrainesDiabetes Continues Its Relentless Rise1st Drug for Tardive Dyskinesia ApprovedHealth Tip: When to Worry About Neck PainChemicals Found in Many U.S. Streams: StudyAHA: Patients Lack Confidence in Managing Their CholesterolAsymptomatic C. difficile Ups Risk for Other Hospital PatientsSilk Clothes Won't Soothe Eczema's ItchHealth Tip: Recognizing Symptoms of Lactose IntoleranceHealth Tip: Should You Be Tested for Kidney Disease?Many Americans Don't Know How to Handle High CholesterolBotox May Help Ease 'Burning Mouth' SyndromeInsulin Resistance Predicts Later Cognitive DeclineMusic Therapy Relieves Post-Op Pain in Spinal Surgery PatientsLower Risk of Gastrointestinal Bleeding for ApixabanBedbugs Building Resistance to More InsecticidesObesity May Make Rheumatoid Arthritis Tough to Spot, TrackXanax, Valium May Boost Pneumonia Risk in Alzheimer's PatientsU.S. Blood Banks Can Protect Blood Supply From Zika VirusHow to Protect Yourself From Air PollutionIntestinal Reovirus Infection May Be Cause of Celiac DiseaseFDA Approves Hep C Drugs for Kids 12 and Older
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

1st Drug for Tardive Dyskinesia Approved

HealthDay News
by -- Scott Roberts
Updated: Apr 12th 2017

WEDNESDAY, April 12, 2017 (HealthDay News) -- Ingrezza (valbenazine), the first drug to treat adults with the neurological disorder tardive dyskinesia, has been approved by the U.S. Food and Drug Administration.

The disorder is characterized by repetitive involuntary movements, usually of the jaw, lips and tongue. Affected people may stick out the tongue, smack the lips, involuntarily move the arms and legs, and have trouble breathing, the FDA said in a news release.

The disorder may be a side effect of older antipsychotic medications to treat conditions such as schizophrenia, depression or bipolar disorder. It's not known why some users of these medications develop tardive dyskinesia, while others don't, the agency said.

"Tardive dyskinesia can be disabling and can further stigmatize patients with mental illness," said Dr. Mitchell Mathis, director of the FDA's Division of Psychiatry Products. "Approving the first drug for the treatment of tardive dyskinesia is an important advance for patients suffering with this condition."

Ingrezza's effectiveness was established in a clinical study of 224 people that compared the drug to a placebo. Potential side effects included sleepiness and abnormal heartbeat. Anyone taking Ingrezza should not drive or use heavy machinery until the effects of the drug on the person are known, the FDA warned.

Approval of Ingrezza was given to Neurocrine Biosciences, based in San Diego.

More information

To learn more, visit the FDA.